AR023687A1 - Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa - Google Patents

Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa

Info

Publication number
AR023687A1
AR023687A1 ARP990105400A ARP990105400A AR023687A1 AR 023687 A1 AR023687 A1 AR 023687A1 AR P990105400 A ARP990105400 A AR P990105400A AR P990105400 A ARP990105400 A AR P990105400A AR 023687 A1 AR023687 A1 AR 023687A1
Authority
AR
Argentina
Prior art keywords
treatment
external retina
retina disorders
manufacture
composition
Prior art date
Application number
ARP990105400A
Other languages
English (en)
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of AR023687A1 publication Critical patent/AR023687A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una composicion para el tratamiento de desordenes de la retina externa, que comprende una cantidad farmacéuticamente efectiva de un antagonista deglutamato y uso de una cantidad farmacéuticamente efectiva de un antagonista de glutamato porque es parala manufactura de un medicamento para el tratamientode desordenes de la retina externa.
ARP990105400A 1998-10-27 1999-10-26 Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa AR023687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10571298P 1998-10-27 1998-10-27

Publications (1)

Publication Number Publication Date
AR023687A1 true AR023687A1 (es) 2002-09-04

Family

ID=22307389

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105400A AR023687A1 (es) 1998-10-27 1999-10-26 Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa

Country Status (12)

Country Link
US (1) US6509355B1 (es)
EP (1) EP1126850A4 (es)
JP (1) JP2002528416A (es)
KR (1) KR20020002356A (es)
CN (1) CN1324240A (es)
AR (1) AR023687A1 (es)
AU (1) AU761824B2 (es)
BR (1) BR9914848A (es)
CA (1) CA2347863C (es)
TR (1) TR200101149T2 (es)
WO (1) WO2000024396A1 (es)
ZA (1) ZA200103236B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000129A1 (en) * 1997-06-30 1999-01-07 Dreyer Evan B Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
US7186745B2 (en) 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050283109A1 (en) * 2003-03-07 2005-12-22 Peyman Gholam A Method and apparatus for lacrimal canal obstruction
US7220224B1 (en) * 2003-03-07 2007-05-22 Minu, Llc Retinal translocation and fixation using adhesive material
US20050130878A1 (en) * 2003-11-26 2005-06-16 Alcon, Inc. Prevention of photic injury by administering a TACE inhibitor
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
WO2008098027A2 (en) * 2007-02-06 2008-08-14 Allergan, Inc. Treatment of ischemic retinal conditions with memantine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
FR2717080B1 (fr) 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5604244A (en) 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
FR2738567B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
WO1997009309A1 (fr) 1995-09-08 1997-03-13 Synthelabo Derives de 4-(cycloalkyl)piperidines et de 4-(cycloalkylalkyl)pi peridines, leur preparation et leur application en therapeutique
CA2241913A1 (en) * 1996-01-02 1997-07-10 Synthelabo Use of polyamine site antagonist for the manufacture of a medicament for the treatment of ischemic disorders of the eye
WO1999000129A1 (en) * 1997-06-30 1999-01-07 Dreyer Evan B Calcium blockers to treat proliferative vitreoretinopathy

Also Published As

Publication number Publication date
EP1126850A1 (en) 2001-08-29
CA2347863C (en) 2009-05-05
KR20020002356A (ko) 2002-01-09
TR200101149T2 (tr) 2001-10-22
AU1516900A (en) 2000-05-15
WO2000024396A1 (en) 2000-05-04
US6509355B1 (en) 2003-01-21
ZA200103236B (en) 2001-10-23
JP2002528416A (ja) 2002-09-03
CN1324240A (zh) 2001-11-28
AU761824B2 (en) 2003-06-12
EP1126850A4 (en) 2003-01-15
WO2000024396A9 (en) 2000-09-28
CA2347863A1 (en) 2000-05-04
BR9914848A (pt) 2001-07-10

Similar Documents

Publication Publication Date Title
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
AR037109A1 (es) Uso de flibanserina
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
AR035158A1 (es) Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
UY26376A1 (es) Combinaciones sinteticas de un antagonista de nk1 y un analogo estructural de gaba
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
AR014082A1 (es) Concentrado oral de sertralina
SE0000303D0 (sv) Novel compounds
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación

Legal Events

Date Code Title Description
FA Abandonment or withdrawal